Contrasting Prenetics Global (PRE) & Its Rivals

Prenetics Global (NASDAQ:PREGet Rating) is one of 729 publicly-traded companies in the “Holding & other investment offices” industry, but how does it contrast to its peers? We will compare Prenetics Global to related businesses based on the strength of its dividends, risk, profitability, analyst recommendations, earnings, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current ratings and price targets for Prenetics Global and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prenetics Global 0 0 2 0 3.00
Prenetics Global Competitors 116 592 886 15 2.50

Prenetics Global currently has a consensus target price of $7.00, indicating a potential upside of 760.90%. As a group, “Holding & other investment offices” companies have a potential upside of 63.33%. Given Prenetics Global’s stronger consensus rating and higher possible upside, equities analysts clearly believe Prenetics Global is more favorable than its peers.

Earnings & Valuation

This table compares Prenetics Global and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Prenetics Global $275.76 million -$3.31 million -0.15
Prenetics Global Competitors $1.21 billion -$4.81 million 23.49

Prenetics Global’s peers have higher revenue, but lower earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Prenetics Global pays an annual dividend of $2.80 per share and has a dividend yield of 344.4%. Prenetics Global pays out -52.6% of its earnings in the form of a dividend. As a group, “Holding & other investment offices” companies pay a dividend yield of 11.8% and pay out -451.1% of their earnings in the form of a dividend.

Institutional and Insider Ownership

13.0% of Prenetics Global shares are held by institutional investors. Comparatively, 65.6% of shares of all “Holding & other investment offices” companies are held by institutional investors. 7.8% of Prenetics Global shares are held by insiders. Comparatively, 18.5% of shares of all “Holding & other investment offices” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Prenetics Global has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, Prenetics Global’s peers have a beta of 0.05, meaning that their average stock price is 95% less volatile than the S&P 500.


This table compares Prenetics Global and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Prenetics Global N/A N/A N/A
Prenetics Global Competitors 7.62% -78.02% 2.09%


Prenetics Global peers beat Prenetics Global on 9 of the 15 factors compared.

About Prenetics Global

(Get Rating)

Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with's FREE daily email newsletter.